Cardiovascular disease remains the leading cause of death globally, with arterial plaque formation representing a critical inflection point between health and disease. Understanding the molecular switches that drive foam cell formation—the cholesterol-laden immune cells that form atherosclerotic plaques—could unlock new therapeutic approaches for millions at risk. This research identifies FLRT2 as a previously unrecognized molecular brake on the body's natural cholesterol removal system, offering a potential target for intervention.
The study demonstrates that FLRT2 protein interferes with a crucial cellular housekeeping process involving USP22 and ABCA1. ABCA1 serves as the primary cholesterol transporter that helps cells eliminate excess cholesterol, preventing the dangerous accumulation that characterizes foam cells. When FLRT2 levels increase, it blocks USP22's ability to stabilize ABCA1 through deubiquitination, effectively dismantling the cell's cholesterol export machinery. This molecular cascade transforms healthy macrophages into foam cells, accelerating atherosclerotic plaque development.
This finding represents a significant advance in atherosclerosis research by revealing how protein modification systems regulate cholesterol homeostasis. The FLRT2-USP22-ABCA1 pathway provides a mechanistic explanation for why some individuals develop aggressive atherosclerosis despite standard risk factors. From a therapeutic perspective, this pathway offers multiple intervention points—potentially through FLRT2 inhibitors or USP22 activators. However, this appears to be early-stage mechanistic research, likely conducted in cell culture or animal models. The clinical relevance for human atherosclerosis treatment remains to be established through larger studies examining FLRT2 expression in human arterial tissue and its correlation with cardiovascular outcomes.